Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported ... So it's really about continued serving of patient living with diabetes [and] obesity, both in the U.S." Susannah Streeter ...

A drug that Novo Nordisk acquired to expand its ... Targeting it for obesity was validated by rimonabant (brand name Acomplia), a Sanofi drug approved in Europe in 2006. But hitting CB1 receptors ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.